Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Seasonal influenza virus vaccine quadrivalent - Sanofi Pasteur

Drug Profile

Seasonal influenza virus vaccine quadrivalent - Sanofi Pasteur

Alternative Names: FluQuadri; FluQuadri Junior; Fluzone QIV ID; Fluzone QIV IM; Fluzone Quadrivalent; Fluzone Quadrivalent vaccine; High-Dose Influenza Vaccine Quadrivalent; QIV; QIV-HD; Quadrivalent inactivated influenza virus vaccine; Quadrivalent influenza vaccine; Shenzhen quadrivalent influenza vaccine; Shz QIV; Vaxigrip QIV IM; VaxigripTetra

Latest Information Update: 25 Jan 2019

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator sanofi pasteur
  • Developer Sanofi K.K.; Sanofi Pasteur
  • Class Influenza virus vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Influenza virus infections

Most Recent Events

  • 23 Jan 2019 The USFDA approves the use of the 0.5 mL dose of seasonal influenza virus vaccine quadrivalent in children age 6 through 35 months
  • 05 Dec 2018 Sanofi plans a phase III trial for Influenza virus infections (In children, In adults) in December 2018 (NCT03765437)
  • 18 Sep 2018 Sanofi Pasteur initiates enrolment in a phase II trial for Influenza virus infections (In adolescents, In children, In infants, Prevention) in USA (IM) (NCT03698279)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top